Sandoz Of Novartis AG (NYSE:NVS) Acquires Antibiotics Of GlaxoSmithKline Plc (NYSE:GSK) For $500 Million

Novartis AG (NYSE:NVS)’s Sandoz entered a deal with GlaxoSmithKline Plc (NYSE:GSK) to acquire the established antibiotic brands like Fortum, Zinacef, and Zinnat for $350 million. GlaxoSmithKline will also receive milestone payments of up to $150 million. The deal will be closed by the end of this year. Sandoz decided to purchase antibiotics brands after it […]

Agenus Inc (NASDAQ:AGEN) Plays An Important Role Towards The Development Of The First Malaria Vaccine That Is Set To Be Tested In Africa

The World Health Organization on Monday moved ahead to state that the world’s first malaria vaccine, which a matter of fact is constituted by a key component manufactured by Agenus Inc (NASDAQ:AGEN) will be made accessible to patients in different parts of Africa from early next year. An African officer working with WHO has gone ahead […]

Plandai Biotechnology Inc (OTCMKTS:PLPL) Extends Its Association With USN (EDXC, GILD)

Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that Ultimate Sports Nutrition is designing a new product line targeting the New Zealand and Australian markets. This line of products will be formulated using company’s patented Phytofare® complex. As per the new contract, the USN can assess the applications of the Phytofare® with other contract manufacturers. The idea is […]

Pfizer Inc. (NYSE:PFE) and SV Life Sciences Fund Autifony Therapeutics For Schizophrenia Research

Pfizer Inc. (NYSE:PFE) has teamed up with and SV Life Sciences to fund Autifony Therapeutics, a spin-off from GlaxoSmithKline plc (ADR) (NYSE:GSK) on research for schizophrenia treatments. The pharmaceutical industry has been extremely busy over the past year, especially with many firms merging or taking part in acquisitions. The aim of such endeavors is to […]

GlaxoSmithKline plc (ADR) (NYSE:GSK) Sells Two Vaccines to Pfizer Inc. (NYSE:PFE) to Relax Antitrust Issues

GlaxoSmithKline plc (ADR) (NYSE:GSK) has struck a deal with Pfizer Inc. (NYSE:PFE) where the latter will buy two of Glaxo’s vaccines for about $30 million. The vaccines are designed for global efforts to prevent meningococcal disease. Pfizer consented to acquire the two drugs, namely Mencevax and Nimenrix that will both be used as single doses […]

Call Buyers Active In GlaxoSmithKline plc (ADR)(NYSE:GSK)

GlaxoSmithKline plc (ADR)(NYSE:GSK) is one the U.K. stocks that have hardly fetched any attention of options traders. However, on Friday’s trading session, the call buyers are seen making position in company’s stock. The volume in GSK contracts jumped to the record level since 2007, with traders willing to pay higher premiums for bullish options compared […]

GlaxoSmithKline plc (ADR) (NYSE:GSK) Unit Invests In PsiOxus Therapeutics $39 Million Fund Raising

The SR One VC unit of GlaxoSmithKline plc (ADR) (NYSE:GSK) has contributed in the Series C $39 million funding round of PsiOxus Therapeutics. The company is raising funds for conducting clinical trials of an oncolytic virus treatment with a checkpoint inhibitor. The fundraising has been initiated after the Phase 1 trial results of a study […]

Analysts Not Impressed With GlaxoSmithKline plc (ADR) (NYSE:GSK) And CEO Andrew Witty

Analysts are hoping that GlaxoSmithKline plc (ADR) (NYSE:GSK) can stabilize the company amid a series of new strategies that the CEO, Andrew Witty, has been implementing in recent months. Bernstein analyst Tim Anderson has reviewed the company that decided to let go of the cancer treatment drugs and focus instead on the vaccine groups. Anderson […]

GlaxoSmithKline plc (ADR) (NYSE:GSK) Bankrolls A Tiny Startup In Search Of An HIV Cure

GlaxoSmithKline plc (ADR) (NYSE:GSK) will team up with the University of North Carolina to form a spinoff that will initially put all its focus on the search for a cure for HIV. The company has been experiencing some rough times and will allocate some of its resources to the joint venture that it hopes will […]

GlaxoSmithKline Plc (ADR) (NYSE:GSK) Unveils Big Business Growth Targets

On Wednesday, GlaxoSmithKline plc (ADR) (NYSE:GSK) divulged its growth goals. This is an endeavor to persuade investors that concentrating on consumer health and vaccines would bring back long-term growth. It also discarded plans to float its HIV drug business ViiV Healthcare pointing to its strong outlook. Further, it pledged to disburse a regular dividend of […]

GlaxoSmithKline plc (ADR) (NYSE:GSK) files Gene Therapy in Europe

GlaxoSmithKline plc (ADR) (NYSE:GSK) and its partner San Raffaele Telethon Institute for Gene Therapy have started marketing a gene therapy for hyper rare cases of immune deficiency. The immune deficiency is triggered by ADA-SCID. The delivery of the therapy to regulators comes in the backdrop of some prominent setbacks that have begun to cloud what […]

Pfizer Inc. (NYSE:PFE) – Testing Support Band In $33.50-$34.00

Pfizer Inc. (NYSE:PFE) spent the last trading session almost flat as it ended the day with a minor loss of 0.55% but the next trading may take a different color after the announcement of the last quarterly results. The company has beat the street estimates overcoming the patent expirations and Dollar strength but the guidance […]

Ebola Fears: Drug And Suit Makers Up In The Market

Boston, MA 10/13/2014 (wallstreetpr) – The Ebola menace is slowly finding its way in the U.S. after a nurse who cared for an Ebola patient was also diagnosed with the virus. Companies developing cures for the diseases lead by Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) and Sarepta Therapeutics Inc. (NASDAQ:SRPT) have been on an upward swing. Focus […]

GlaxoSmithKline plc (ADR) (NYSE:GSK) Starts Making New Doses Of Ebola Vaccine As Ebola Enters America

Boston, MA 10/06/2014 (wallstreetpr) – According to reports, Ebola; the deadliest virus of the present has entered in America. Recently two new cases of Ebola were found in Texas. As soon as the news was confirmed, various drug manufacturing companies started coming out with their Ebola Vaccines at earliest. Among all these companies, GlaxoSmithKline plc (ADR) […]

NewLink Genetics Corp (NASDAQ:NLNK) and GlaxoSmithKline plc (ADR) (NYSE:GSK) To Come Out With Vaccines To Treat Ebola

Boston, MA 10/02/2014 (wallstreetpr) – Biopharmaceutical company, NewLink Genetics Corp (NASDAQ:NLNK), and a global healthcare company, GlaxoSmithKline plc (ADR) (NYSE:GSK), are working to develop vaccines to treat Ebola. The product is likely to come out in the first six months of the next year. Ebola virus has been spreading the world over after the latest outbreak […]